FLD Market Analysis
Wall Street coverage
third-party contextWall Street coverage
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
48 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeValuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 0.63
- P/S (TTM)
- 0.75
- EV/EBITDA
- 4.04
Profitability & growth
- ROE (TTM)
- -92.2%
- Operating margin
- -167.0%
- Revenue growth YoY
- -21.1%
- Dividend yield
- —
- Beta
- 0.36
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Fold Holdings, Inc. Class A Common Stock
Company profileFold Holdings, Inc. (FLD) is an innovative biotechnology firm dedicated to the development of groundbreaking therapies for severe genetic and rare diseases, utilizing advanced research methodologies and proprietary technologies. With a promising product pipeline bolstered by strategic collaborations, the company is poised to capitalize on substantial market opportunities within the healthcare sector. Fold's steadfast focus on scientific excellence and patient-centered solutions underscores its potential as a significant investment prospect, offering the promise of long-term growth and…
Classification
- Sector
- Financial Services
- Industry
- Capital Markets
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 2942 NORTH 24TH STREET, PHOENIX, AZ
- Fiscal year end
- December
- Latest quarter
- Mar 31, 2026
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
